Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Breast Cancer
HER2-Positive Breast Cancer and CDK4/6 Inhibitors
By
Dr Hope Rugo
Breast Cancer
,
SABCS Highlights
Videos
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2-positive breast cancer.
Read Article
Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
By
Dr Hope Rugo
Breast Cancer
,
SABCS Highlights
Videos
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor.
Read Article
What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
By
Dr Hope Rugo
Breast Cancer
,
SABCS Highlights
Videos
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Read Article
CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
By
Dr Hope Rugo
Breast Cancer
,
SABCS Highlights
Videos
Read Article
Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
By
Dr Hope Rugo
Breast Cancer
,
SABCS Highlights
Videos
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
Read Article
Hot Topics at SABCS 2017
By
Dr Hope Rugo
Breast Cancer
,
SABCS Highlights
Videos
Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more.
Read Article
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—The addition of the investigational CDK4/CDK6 inhibitor abemaciclib to fulvestrant (Faslodex) extended progression-free survival (PFS) by 7 months in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, reported George W. Sledge, Jr, MD, Professor, Medical Oncology, Stanford University Medical Center, Palo Alto, CA, who presented the results of a large study at the 2017 ASCO annual meeting.
Read Article
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with standard chemotherapy in women with HER2-negative metastatic breast cancer with a germline
BRCA
mutation. Disease progression was delayed by approximately 3 months with olaparib in the multinational, randomized, open-label, phase 3 OlympiAD clinical trial, reported Mark E. Robson, MD, Clinic Director, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting.
Read Article
Excellent Responses to Atezolizumab in Small Subset of Women with Triple-Negative Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
June 2017, Vol 8, No 3
Washington, DC—Preliminary data show excellent and durable responses to atezolizumab (Tecentriq) in 10% of women with triple-negative breast cancer, one of the most aggressive and difficult-to-treat cancers. Of the responders to atezolizumab, 100% were alive at 1 year compared with only 38% of nonresponders. The trick will be to identify which women will respond to immune checkpoint inhibitor therapy. Thus far, no biomarkers for response have been identified.
Read Article
Impact of Elevated Tumor-Infiltrating Lymphocytes Differs Across Breast Cancer Subtypes
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
June 2017, Vol 8, No 3
San Antonio, TX—Concentrations of tumor-infiltrating lymphocytes (TILs) had significant but variable associations with survival in breast cancer, according to 2 large retrospective studies of pathology specimens reported at the 2016 San Antonio Breast Cancer Symposium.
Read Article
Page 6 of 13
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma